Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lori Styles, MD
Pharmacyclics LLC.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
108 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator #654
Kogarah, New South Wales, Australia
- Site Reference Id/investigator #503
Woolloongabba, Queensland, Australia
- Site Reference Id/investigator #163
Bedford Park, South Australia, Australia
- Site Reference Id/investigator #555
Hobart, Tasmania, Australia
- Site Reference Id/investigator #193
Box Hill, Victoria, Australia
- Site Reference Id/investigator #556
Clayton, Victoria, Australia
- Site Reference Id/investigator #501
Fitzroy, Victoria, Australia
- Site Reference Id/investigator #715
Frankston, Victoria, Australia
- Site Reference Id/investigator #558
Geelong, Victoria, Australia
- Site Reference Id/investigator #170
Heidelberg, Victoria, Australia
- Site Reference Id/investigator #164
Brussels, Brussells, Belgium
- Site Reference Id/investigator #727
Yvoir, Namur, Belgium
- Site Reference Id/investigator #560
Ghent, Oost-Vlaanderen, Belgium
- Site Reference Id/investigator #559
Leuven, Vlaams Brabant, Belgium
- Site Reference Id/investigator #628
Bruges, West-Vlaanderen, Belgium
- Site Reference Id/investigator #561
Antwerp, Belgium
- Site Reference Id/investigator #184
Brussells, Belgium
- Site Reference Id/investigator #157
Calgary, Alberta, Canada
- Site Reference Id/investigator #018
Edmonton, Alberta, Canada
- Site Reference Id/investigator #159
Ottawa, Ontario, Canada
- Site Reference Id/investigator #674
Guangzhou, Guangdong, China
- Site Reference Id/investigator #671
Nanjing, Jiangsu, China
- Site Reference Id/investigator #675
Hangzhou, Zhejiang, China
- Site Reference Id/investigator #670
Beijing, China
- Site Reference Id/investigator #673
Beijing, China
- Site Reference Id/investigator #564
Hradec Králové, Hradec Králové Region, Czechia
- Site Reference Id/investigator #562
Brno, Czechia
- Site Reference Id/investigator #566
Plzen-Lochotin, Czechia
- Site Reference Id/investigator #570
Dublin, Ireland
- Site Reference Id/investigator #572
Dublin, Ireland
- Site Reference Id/investigator #571
Galway, Ireland
- Site Reference Id/investigator #573
Haifa, Israel
- Site Reference Id/investigator #576
Haifa, Israel
- Site Reference Id/investigator #577
Jerusalem, Israel
- Site Reference Id/investigator #578
Nahariya, Israel
- Site Reference Id/investigator #575
Petah Tikva, Israel
- Site Reference Id/investigator #574
Ramat Gan, Israel
- Site Reference Id/investigator #583
Rome, Lazio, Italy
- Site Reference Id/investigator #522
Rozzano, Milano, Italy
- Site Reference Id/investigator #582
Novara, Piedmont, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2013
- Primary completion
- 31 May 2015
- Completion
- 31 May 2015
- Last update posted
- 30 Nov 2017
- Registered enrollment
- 269
- Registry id
- NCT01722487
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.